Let's collaborate and create quality liposome encapsulated drugs together. Contact Us!
September 27, 2023SyVento BioTech Participates in the Polish-British Future of Healthcare Event
LONDON, September 26, 2023 – The Polish-British Future of Healthcare Event, focusing on advancements in MedTech, BioTech, and scientific research, will soon take place at the Royal Society of Medicine. SyVento BioTech will be represented by Tomasz Piec, Chairman of the Supervisory Board, and Dominik Lipka, our CTO. International Cooperation in BioTech: A Business Imperative […]
September 11, 2023SyVento BioTech Partners with LifeScience Kraków Cluster: A Global Vision with Local Roots
SyVento BioTech Partners with LifeScience Kraków Cluster: A Global Vision with Local Roots In a strategic move that aims to consolidate our position as a leader in biotechnology and life sciences, SyVento BioTech is proud to announce our official partnership with the LifeScience Kraków Cluster. Established in 2006, the LifeScience Kraków Cluster has consistently served […]
August 31, 2023SyVento BioTech at the Forefront of RNA Therapeutics and Vaccines Conference
In an era where breakthroughs in RNA therapeutics are revolutionizing medicine, SyVento BioTech’s expertise in Lipid Nanoparticle (LNP) formulations stands out as a beacon. LNPs are pivotal for the efficient delivery of mRNA-based drug products, and our team has been pioneering advancements in this domain. It’s with this background that we are thrilled to announce […]
August 24, 2023SyVento BioTech at PHASE 2023 Conference
SyVento BioTech at PHASE 2023 Conference The PHASE 2023 Conference stood as one of the most crucial discussions in the Polish biotech arena. It highlighted the present situation, outlined objectives, and shed light on both the opportunities available and the challenges to address. Events like these are instrumental in propelling the biotech industry in Poland […]
August 1, 2023Reflecting on Our Participation in the 13th International Scientific Conference on Alkaptonuria
We are proud to look back on our participation in the recently concluded 13th International Scientific Conference on Alkaptonuria (AKU) that took place in Bratislava, Slovakia. This significant event brought together AKU researchers, academics, and clinicians from all over the world. Our team was represented by our R&D Director, Dominik Lipka, PhD Eng., and […]
June 6, 2023Aktualizacja Siedziby SyVento Sp. z o.o. / Change of Registered Office of SyVento sp. z o.o.
Jest nam niezmiernie miło poinformować, że SyVento Sp. z o.o. z dniem 5 czerwca 2023 roku oficjalnie przenosi swoją siedzibę. Nowy adres wpisany do Krajowego Rejestru Sądowego przez Sąd Rejestrowy to: ul. Za Górą 19, 32 – 050 Skawina. Ta zmiana jest bezpośrednim wynikiem naszej inwestycji w Centrum Badań i Rozwoju Biotechnologicznego w Skawinie oraz […]
June 6, 2023SyVento BioTech Attends BIO International Convention 2023
SyVento BioTech Attends BIO International Convention 2023 SyVento BioTech is currently participating in the BIO International Convention 2023. The organization’s representatives at this event are Business Development Manager Dr. Oskar Szelest, R&D Director Dominik Lipka, PhD Eng., and Chairman of the Supervisory Board, Tomasz Piec. This convention is hosting over 15,000 biotechnology and pharmaceutical leaders […]
March 13, 2023RNA Leaders Europe Congress – Meet us at stand 16
Tomasz Piec, President of Supervisory Board, Dominik Lipka, PhD Eng., Director of Research and Development, Board Member, and Oskar Szelest, PhD, Business Development Manager, will be attending this year’s RNA Leaders conference.
December 9, 2021SyVento and OncoArendi agreement
SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. Details in following press release.